Rossari Biotech Limited
Rossari Biotech Limited Fundamental Analysis
Rossari Biotech Limited (ROSSARI.NS) shows moderate financial fundamentals with a PE ratio of 19.84, profit margin of 6.01%, and ROE of 11.62%. The company generates $22.9B in annual revenue with strong year-over-year growth of 13.64%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 55.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ROSSARI.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakROSSARI.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateROSSARI.NS shows balanced valuation metrics.
Growth Score
ModerateROSSARI.NS shows steady but slowing expansion.
Financial Health Score
ExcellentROSSARI.NS maintains a strong and stable balance sheet.
Profitability Score
WeakROSSARI.NS struggles to sustain strong margins.
Key Financial Metrics
Is ROSSARI.NS Expensive or Cheap?
P/E Ratio
ROSSARI.NS trades at 19.84 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ROSSARI.NS's PEG of 25.77 indicates potential overvaluation.
Price to Book
The market values Rossari Biotech Limited at 2.18 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.67 times EBITDA. This is generally considered low.
How Well Does ROSSARI.NS Make Money?
Net Profit Margin
For every $100 in sales, Rossari Biotech Limited keeps $6.01 as profit after all expenses.
Operating Margin
Core operations generate 12.90 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.62 in profit for every $100 of shareholder equity.
ROA
Rossari Biotech Limited generates $6.59 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Rossari Biotech Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Rossari Biotech Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ROSSARI.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
19.84
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
25.77
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.18
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.19
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.28
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.20
vs 25 benchmark
How ROSSARI.NS Stacks Against Its Sector Peers
| Metric | ROSSARI.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 19.84 | 27.18 | Better (Cheaper) |
| ROE | 11.62% | 860.00% | Weak |
| Net Margin | 6.01% | -121084.00% (disorted) | Weak |
| Debt/Equity | 0.28 | 0.41 | Strong (Low Leverage) |
| Current Ratio | 1.73 | 4.81 | Neutral |
| ROA | 6.59% | -7173.00% (disorted) | Weak |
ROSSARI.NS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Rossari Biotech Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
205.36%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
83.51%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
120.11%
Industry Style: Cyclical, Commodity, Value
High Growth